Internal Reference Number: FOI_6440
Date Request Received: 19/01/2022 00:00:00
Date Request Replied To: 04/02/2022 00:00:00
This response was sent via: By Email
Request Summary: Dermatology department use of biologic drugs
Request Category: Companies
| Question Number 1: Please provide the numbers of patients treated in the last 3 months by the Dermatology department (for any medical condition) with the following biologic drugs: • Adalimumab - Humira • Adalimumab Biosimilar • Apremilast • Bimekizumab • Brodalumab • Certolizumab • Dimethyl fumarate • Etanercept - Enbrel • Etanercept Biosimilar • Guselkumab • Infliximab - Remicade • Infliximab Biosimilar • Ixekizumab • Risankizumab • Secukinumab • Tildrakizumab • Ustekinumab | |
| Answer To Question 1: Adalimumab Humira 6 Adalimumab biosimilar 23 Apremilast 2 Bimekizumab 0 Brodalumab 9 Certolizumab 4 Dimethyl Fumarate 0 Etanercept Enbrel 0 Etanercept biosimilar 0 Guselkumab 10 Infliximab Remicade 0 Infliximab biosimilar 0 Ixekizumab 4 Risankizumab 0 Secukinumab 5 Tildrakizumab 3 Ustekinumab 15 | |
| To return to the list of all the FOI requests please click here |
Our staff at Salisbury District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of ¾¨Ó㴫ý Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
